Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033501 | 0.77 | AGPAT2 (0.44) | ABL1BCRTRPV1MAPTPOLB | |
| SCHEMBL5801265 | 0.76 | TRPV1 (0.59) | ABL1BCRTRPV1HIF1AEPAS1 | |
| SCHEMBL6033570 | 0.75 | CXCR4 (0.49) | MAPT | |
| SCHEMBL6478554 | 0.71 | AGPAT2 (0.48) | ABL1BCRMAPTPOLBEPHX2 | |
| SCHEMBL16704827 | 0.70 | HIF1A (0.82) | HIF1AEPAS1MAPTL3MBTL1 | |
| SCHEMBL3608208 | 0.70 | SLC2A1 (0.47) | TRPV1HIF1AEPAS1MAPTTSHR | |
| SCHEMBL4242830 | 0.69 | CYP2A13 (0.56) | HIF1AEPAS1MAPTSLC2A1POLB | |
| SCHEMBL13771177 | 0.69 | ABL1 (1.00) | ABL1BCRTRPV1HIF1ATSHR | |
| SCHEMBL11001901 | 0.68 | DHODH (0.50) | ABL1BCRTRPV1MAPTPOLB | |
| SCHEMBL1844423 | 0.68 | AGPAT2 (0.53) | ABL1BCRMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685124-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005047279-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | ABL1 989/4885BCR 1760/4885TRPV1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.